HC Wainwright Forecasts Xeris Biopharma Q1 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Xeris Biopharma in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst B. Folkes anticipates that the company will post earnings per share of ($0.03) for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The firm had revenue of $85.81 million for the quarter, compared to analyst estimates of $86.00 million.

Other research analysts have also recently issued research reports about the stock. Piper Sandler boosted their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Oppenheimer reissued an “outperform” rating and set a $18.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Wall Street Zen cut shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Barclays began coverage on Xeris Biopharma in a research note on Monday, December 8th. They set an “overweight” rating and a $9.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.08.

Xeris Biopharma Price Performance

Xeris Biopharma stock opened at $6.04 on Thursday. The company has a current ratio of 2.19, a quick ratio of 1.35 and a debt-to-equity ratio of 16.10. The firm has a market capitalization of $1.04 billion, a P/E ratio of -603.40 and a beta of 0.61. The business has a 50-day moving average of $7.13 and a 200-day moving average of $7.60. Xeris Biopharma has a 1 year low of $3.81 and a 1 year high of $10.08.

Institutional Investors Weigh In On Xeris Biopharma

Several institutional investors have recently bought and sold shares of XERS. Vanguard Group Inc. increased its stake in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares during the last quarter. Geode Capital Management LLC boosted its stake in Xeris Biopharma by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after buying an additional 135,815 shares in the last quarter. State Street Corp boosted its stake in Xeris Biopharma by 10.1% in the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after buying an additional 378,595 shares in the last quarter. Qube Research & Technologies Ltd grew its position in Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after acquiring an additional 185,063 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

Insider Buying and Selling at Xeris Biopharma

In related news, Director John Johnson sold 135,400 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $7.22, for a total value of $977,588.00. Following the sale, the director directly owned 698,083 shares of the company’s stock, valued at approximately $5,040,159.26. The trade was a 16.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $6.25, for a total value of $104,168.75. Following the transaction, the insider owned 1,226,507 shares of the company’s stock, valued at approximately $7,665,668.75. This trade represents a 1.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 240,308 shares of company stock valued at $1,732,453 over the last quarter. 6.47% of the stock is currently owned by corporate insiders.

Key Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating with a $10 price target and published multi‑year EPS upside through 2030, signalling continued analyst conviction in the company’s pipeline and revenue trajectory. HC Wainwright coverage / MarketBeat
• Positive Sentiment: A bullish third‑party piece argues Xeris is undervalued given its drug portfolio, which can attract value/growth investors and support longer‑term demand for the stock. Seeking Alpha: Undervalued thesis
• Positive Sentiment: Aggregate analyst coverage is summarized as a “Moderate Buy,” which helps underpin investor sentiment versus outright bearish coverage. Consensus rating / American Banking News
• Neutral Sentiment: HC Wainwright published specific near‑term estimates (Q1‑2026 EPS est. of ($0.03); FY2026 est. $0.06) that give a roadmap for upcoming results but include mixed signals as Xeris transitions toward expected profitability. HC Wainwright estimates / MarketBeat
• Neutral Sentiment: Consensus full‑year EPS remains negative (around ‑$0.41), so near‑term profitability risk persists until revenue and margin trends consistently improve. Consensus estimates / MarketBeat
• Negative Sentiment: Insider Beth Hecht sold 16,667 shares at an average $6.25 on Mar 2 (Form 4 filed), which some investors view as a negative signal about insider conviction or a source of incremental supply. Insider sale alert / InsiderTrades
• Negative Sentiment: HC Wainwright trimmed several mid/long‑range EPS forecasts (FY2026‑FY2029 revisions downward), reducing some near‑term upside and tempering expectations until revenue growth reaccelerates. Forecast revisions / MarketBeat

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.